<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585789</url>
  </required_header>
  <id_info>
    <org_study_id>CR108790</org_study_id>
    <secondary_id>2019-004475-39</secondary_id>
    <secondary_id>73763989HPB2003</secondary_id>
    <nct_id>NCT04585789</nct_id>
  </id_info>
  <brief_title>A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen&#xD;
      (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based&#xD;
      combination treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">November 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 3, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Percentage of HBsAg Positive Hepatocytes at Week 40</measure>
    <time_frame>Baseline and Week 40</time_frame>
    <description>Change from baseline in the percentage of HBsAg positive hepatocytes at week 40 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Intrahepatic Immune Response</measure>
    <time_frame>Baseline and Week 40</time_frame>
    <description>Change from baseline in intrahepatic immune response will be reported at Week 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Intrahepatic Viral Parameters: HBsAg and HBV DNA</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Change from baseline in intrahepatic viral parameters that is, HBsAg and HBV DNA (units: IU/ml) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Intrahepatic cccDNA and pgRNA levels</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Change from baseline in intrahepatic cccDNA and pgRNA levels will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg Seroclearance at Week 72 Without Restarting Nucleos(t)ide Analog (NA)Treatment</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of participants with HBsAg seroclearance at Week 72 without restarting NA treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with (Sustained) Reduction, Suppression, and/or Seroclearance</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Percentage of participants with (sustained) reduction, suppression, and/or seroclearance will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg and HBeAg Seroconversion</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Percentage of participants with HBsAg and hepatitis B e antigen (HBeAg) seroconversion will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Flares</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Percentage of participants with flares (virologic, biochemical and clinical flares) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve First HBsAg Seroclearance</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Time to achieve first HBsAg seroclearance will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic Breakthrough</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Percentage of participants with virologic breakthrough on treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HBV-specific Peripheral Blood T-cell Responses During the Study Intervention and Follow-up Phases</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Change from baseline in HBV-specific peripheral blood T-cell responses during the study intervention and follow-up phases will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Adverse Events (AEs) and Serious AEs</measure>
    <time_frame>Up to Week 102</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Clinical Laboratory Tests, Electrocardiogram (ECG), Vital Signs And Physical Examination</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Percentage of participants with abnormalities in clinical laboratory tests, ECG, vital signs and physical examination will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of JNJ-73763989 (JNJ-73763976 and JNJ-73763924), JNJ-56136379 and Optionally of NA and/or Pegylated Interferon Alpha-2a (PegIFN-alpha-2a)</measure>
    <time_frame>Days 1, 29, 85, 169, 337</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of JNJ-73763989 (JNJ-73763976 and JNJ-73763924), JNJ-56136379 and optionally of NA and/or PegIFN-alpha-2a.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (last injection at Week 44) along with JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets) once daily up to 48 weeks. Participants may receive optional treatment with pegylated interferon alpha-2a (PegIFN-alpha-2a) after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 1: Arm 2: JNJ-73763989 + NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with NA treatment (either ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: Arm 2: JNJ-73763989 + NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with NA treatment (either ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-73763989</intervention_name>
    <description>JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.</description>
    <arm_group_label>Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 1: Arm 2: JNJ-73763989 + NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 2: JNJ-73763989 + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-56136379</intervention_name>
    <description>JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.</description>
    <arm_group_label>Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir (ETV)</intervention_name>
    <description>ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.</description>
    <arm_group_label>Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 1: Arm 2: JNJ-73763989 + NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 2: JNJ-73763989 + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.</description>
    <arm_group_label>Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 1: Arm 2: JNJ-73763989 + NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 2: JNJ-73763989 + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide (TAF)</intervention_name>
    <description>TAF will be administered orally once daily up to 48 weeks as NA treatment.</description>
    <arm_group_label>Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 1: Arm 2: JNJ-73763989 + NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 2: JNJ-73763989 + NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIFN-alpha-2a</intervention_name>
    <description>PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.</description>
    <arm_group_label>Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 1: Arm 2: JNJ-73763989 + NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA</arm_group_label>
    <arm_group_label>Panel 2: Arm 2: JNJ-73763989 + NA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medically stable on the basis of physical examination, medical history, vital signs,&#xD;
             and triplicate 12-lead electrocardiogram (ECG) performed at screening&#xD;
&#xD;
          -  Hepatitis B virus (HBV) infection with documentation at least 6 months prior to&#xD;
             screening: participants be either currently not treated with HBeAg positive status or&#xD;
             virologically (nucleos[t]ide analog [NA]) suppressed with HBeAg negative status&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) greater than (&gt;) 100 International Units per&#xD;
             Milliliter (IU/mL) at screening&#xD;
&#xD;
          -  Body mass index (BMI) between 18.0 and 35.0 kilogram per meter square (kg/m^2),&#xD;
             extremes included&#xD;
&#xD;
          -  Highly effective contraceptive measures in place for female participants of&#xD;
             childbearing potential or male participants with female partners of childbearing&#xD;
             potential&#xD;
&#xD;
          -  Fibroscan liver stiffness measurement less than and equal to (&lt;=) 9 Kilopascal (kPa)&#xD;
             within 6 months prior to screening or at the time of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of infection with hepatitis A, C, D or E virus infection or evidence of human&#xD;
             immunodeficiency, virus type 1 (HIV-1) or HIV-2 infection at screening&#xD;
&#xD;
          -  History or evidence of clinical signs/symptoms of hepatic decompensation including but&#xD;
             not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal&#xD;
             varices&#xD;
&#xD;
          -  History or signs of cirrhosis or portal hypertension, signs of hepatocellular&#xD;
             carcinoma (HCC) or clinically relevant renal abnormalities on an abdominal ultrasound&#xD;
             performed within 6 months prior to screening or at the time of screening&#xD;
&#xD;
          -  Presence of coagulopathy or bleeding disorder as indicated by: (a) International&#xD;
             normalized ratio (INR) greater than or equal to (&gt;=) 1.1* upper limit of normal (ULN);&#xD;
             (b) Partial thromboplastin time &gt;1.1*ULN; (c) Any signs of prolonged bleeding (&gt;10&#xD;
             minutes)&#xD;
&#xD;
          -  Presence of hemoglobinopathy (including sickle cell disease, thalassemia)&#xD;
&#xD;
          -  Liver biopsy performed prior to screening that led to complications and that in the&#xD;
             opinion of the investigator would prohibit another liver biopsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>ON M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale Maggiore Di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grahame Hayton Unit</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108790</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

